医药行业周报：诺华芦可替尼新适应症在华获批，用于治疗cGVHD

Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine industries, while the biopharmaceutical sector is rated as Neutral [1][6]. Core Insights - As of June 13, 2024, the pharmaceutical sector experienced a decline of 0.96%, underperforming the CSI 300 index by 0.45 percentage points, ranking 12th among 31 sub-industries in the Shenwan classification [3]. - Notable performers within the pharmaceutical sub-industries included blood products (+0.44%) and other biological products (+0.28%), while offline pharmacies (-4.78%) and pharmaceutical distribution (-2.28%) lagged behind [3]. - Recent industry news includes Novartis receiving approval for its JAK inhibitor, ruxolitinib, for a new indication in treating chronic graft-versus-host disease (cGVHD) in patients aged 12 and older [4]. Sub-industry Summary - The report highlights various companies making significant advancements, such as: - Zhongsheng Pharmaceutical's subsidiary receiving approval for a new chemical raw material for treating dry eye syndrome [4]. - Boji Pharmaceutical's subsidiary obtaining approval for a new chemical raw material [4]. - Yiling Pharmaceutical's new drug registration application being accepted by the National Medical Products Administration [4]. - Renfu Pharmaceutical's subsidiary receiving clinical trial approval for a drug aimed at treating partial seizures in patients aged one month and older [4].